Related by context. All words. (Click for frequent words.) 71 AEGR 70 AEZS 70 NKTR 69 ITMN 68 CRx 68 INGN 67 ISIS # 66 Phase Ib 65 ALTU 65 PRTX 65 JAK inhibitor 65 HGS ETR1 64 axitinib 64 Phase 1b 64 MEK inhibitor 64 CUDC 64 Carfilzomib 64 ganetespib 64 INCB# [001] 63 ATHX 63 Phase Ib clinical 63 Bezielle 63 Phase 2a trial 63 ALKS 63 phase IIb clinical 63 4SC 63 PXD# 62 HGS# 62 PRT# 62 Omacetaxine 62 lumiliximab 62 SCH # 62 MEK inhibitors 62 PSN# [002] 62 ENMD 62 polymerase inhibitor 62 dacetuzumab 62 IMMU 62 Sym# 62 BAY #-# 62 phase IIa clinical 62 ENMD # 62 Phase Ib II 62 MORAb 62 GLYX 62 MEDI 61 HuMax CD# 61 Aplidin 61 Perifosine 61 AQ4N 61 cannabinor 61 CIMZIA TM 61 IDX# 61 PEG Interferon lambda 61 PS# [001] 61 Phase 2b 61 oral prodrug 61 PF # [001] 61 HGS ETR2 61 Tyrima 61 PEG SN# 61 bendamustine 61 favorable pharmacokinetic profile 61 Phase Ia 61 Phase 1b trial 61 sunitinib malate 61 Traficet EN 61 Phase IIa clinical 61 GRN#L 61 daclizumab 61 kinase inhibitor 61 preclinically 61 lintuzumab 61 CR# vcMMAE 61 PRX # 61 KRN# 61 ACHN 61 HDAC Inhibitor 61 elotuzumab 61 visilizumab 61 preclinical efficacy 61 Azedra 61 Serdaxin 60 Hsp# inhibitors 60 Phase 2a 60 XL# [003] 60 RGB # 60 otelixizumab 60 pomalidomide 60 MGCD# [002] 60 alvespimycin 60 pan HDAC inhibitor 60 liposomal formulation 60 protein kinase inhibitor 60 HuMax EGFr 60 Mipomersen 60 Pimavanserin 60 LymphoStat B 60 VQD 60 targeting CD# 60 Hsp# inhibitor 60 INCB# [002] 60 Triolex 60 davunetide intranasal AL 60 evaluating tivozanib 60 Aflibercept 60 GLPG# 60 OXi# 59 Amrubicin 59 forodesine 59 mertansine 59 ocrelizumab 59 velafermin 59 MT# MEDI 59 placebo controlled Phase 59 Phase Ib clinical trials 59 MGCD# [001] 59 LEVADEX 59 varespladib 59 Sapacitabine 59 obatoclax 59 Actilon 59 HCV protease inhibitor 59 oral ridaforolimus 59 neratinib 59 phase IIb trial 59 rNAPc2 59 Guanilib 59 pharmacokinetic profile 59 Pazopanib 59 PEG PAL 59 SCY 59 Phase IIb trial 59 AP# [003] 59 Aurora kinase 59 histone deacetylase HDAC inhibitor 59 Cethromycin 59 PDE4 inhibitor 59 eniluracil 59 orally bioavailable 59 belinostat 59 dose cohorts 59 Phase IIa trial 59 phase Ib 59 pharmacodynamic profile 59 teriflunomide 59 preclinical studies 59 Bortezomib 59 anti leukemic 59 glufosfamide 59 Phase Ib study 59 phase IIa 59 LY# [002] 59 mapatumumab 59 CA4P 59 oral FTY# 59 regorafenib 59 docetaxel Taxotere R 59 urocortin 2 59 BNC# 59 HDAC inhibitor 59 phase IIb 59 RDEA# 58 CRTX 58 antitumor activity 58 iCo 58 PCK# 58 enzastaurin 58 investigational oral 58 IMC A# 58 HSP# inhibitor 58 CoFactor 58 MAGE A3 ASCI 58 BRAF inhibitor 58 pertuzumab 58 IPL# 58 TG# [003] 58 tolerability profile 58 Phase IIb clinical 58 Seliciclib 58 Archexin 58 CCR9 antagonist 58 oral antiviral 58 Debio 58 Phase IIa 58 Zybrestat 58 atacicept 58 XmAb# 58 Phase IIa trials 58 cilengitide 58 KSP inhibitor 58 TELINTRA 58 Bicifadine 58 Alocrest 58 Aclidinium 58 nitazoxanide 58 relapsed multiple myeloma 58 injectable formulation 58 GSK# [001] 58 elagolix 58 pharmacodynamic 58 RG# [001] 58 HQK 58 telaprevir VX 58 Alpharadin 58 angiogenesis inhibitor 58 Phase 2b trial 58 brivaracetam 58 CD# antibody [001] 58 YONDELIS 58 Daclizumab 58 XOMA 58 phase 2a 58 Phase 1b clinical 58 Phase IIb trials 58 PSMA ADC 58 eprotirome 58 OncoVEX GM CSF 58 carfilzomib 58 teduglutide 58 alagebrium 58 INC# 58 Phase 2b Clinical Trial 58 Nanobody 58 Gemin X 58 SRT# [003] 58 SARMs 58 Xanafide 57 phase IIb study 57 HspE7 57 Tarvacin 57 selective androgen receptor modulator 57 Symadex 57 AVONEX ® 57 tanespimycin 57 SGEN 57 CYC# 57 Phase 2a clinical 57 HuLuc# 57 ALD# 57 compound INCB# 57 Phase IIb 57 fosbretabulin 57 investigational compound 57 ThermoDox R 57 ISENTRESS 57 lupus nephritis 57 IFN α 57 MAP# 57 ixabepilone 57 metaglidasen 57 ATL# [001] 57 Phase 2b study 57 Panzem 57 gefitinib Iressa 57 MNTX 57 NP2 Enkephalin 57 VEGF Trap 57 Lacosamide 57 ponatinib 57 orally administered inhibitor 57 mTOR inhibitor 57 Dapagliflozin 57 CRLX# 57 darapladib 57 Peregrine Pharmaceuticals 57 HuMax CD4 57 iniparib 57 AEG# 57 tezampanel 57 Virulizin ® 57 erlotinib Tarceva ® 57 midstage clinical 57 cetuximab Erbitux R 57 NXL# 57 NVA# 57 Golimumab 57 Panzem R NCD 57 humanized monoclonal antibody 57 dexpramipexole 57 seliciclib 57 pradefovir 57 Tezampanel 57 LY# [003] 57 FOLOTYN ® 57 vidofludimus 57 resolvin 57 DVAX 57 lexidronam injection 57 AKT inhibitor 57 Entremed 57 Telcyta 57 KSP inhibitors 57 Cloretazine ® 57 Omacetaxine mepesuccinate 57 ELACYT 57 Ocrelizumab 57 CCX# 57 sorafenib Nexavar 57 Cethrin 57 solithromycin 57 virus HCV protease inhibitor 57 imetelstat 57 receptor tyrosine kinase inhibitor 57 XL# XL# XL# 57 Nuvion 57 JAK1 57 lomitapide 57 hour bronchodilation 57 T DM1 57 Plicera 57 huC# DM4 57 Keryx Biopharmaceuticals 57 Epothilone D 57 HCV protease inhibitors 57 RVX 57 valopicitabine 57 Synavive 57 dose escalation trial 57 dirucotide 56 CORT # 56 multi kinase inhibitor 56 bevirimat 56 SPC# [001] 56 bicifadine 56 GALNS 56 ADX# 56 antiviral activity 56 CD# monoclonal antibody 56 Firazyr 56 oral Hsp# inhibitor 56 Ceflatonin 56 talactoferrin 56 fostamatinib 56 Quinamed 56 ORMD 56 huN# DM1 56 Preclinical studies 56 EndoTAG TM -1 56 Zenvia Phase III 56 GW# [003] 56 Ridaforolimus 56 non nucleoside inhibitor 56 RG# ITMN 56 DAVANAT 56 Arqule 56 Troxatyl 56 administered subcutaneously 56 INNO 56 delta isoform 56 selectively inhibits 56 linaclotide 56 amrubicin 56 Exelixis XL# 56 ProSavin 56 R#/MEM # 56 BIBW 56 mipomersen 56 ALGRX 56 JAK inhibitors 56 Linaclotide 56 CDK inhibitor 56 diabetic neuropathic pain 56 Phenoptin 56 relapsed refractory multiple myeloma 56 immunomodulator 56 Laquinimod 56 TOPIGEN 56 nucleoside analog 56 CERE 56 Phase III clinical 56 double blinded placebo 56 OMP #M# 56 Phase 1a clinical 56 ascending doses 56 selective modulator 56 zalutumumab 56 perifosine 56 Phase 2b clinical 56 pharmacodynamics 56 SNT MC# 56 IMA# 56 lixivaptan 56 CytoFabTM 56 radezolid 56 ataluren 56 HCV protease 56 TRV# [001] 56 CBLC# 56 angiotensin receptor blocker ARB 56 ZYBRESTAT 56 ofatumumab 56 Nasulin 56 ESBA# 56 volociximab 56 ALN HPN 56 zanolimumab 56 tafamidis 56 antitumor effects 56 preclinical 56 CaPre TM 56 vinca alkaloid 56 Epratuzumab 56 VAPRISOL 56 CYT# 56 CG# [003] 56 atrasentan 56 investigational humanized monoclonal antibody 56 apremilast 56 stated Michelle Berrey 56 MSI #F 56 ongoing Phase 1b 56 Phase 1a 56 bortezomib 56 EFAPROXYN 56 Ostarine 56 telomerase inhibitor drug 56 Synta Pharmaceuticals 56 Glufosfamide 56 Aurora kinase inhibitor 56 SAR# [004] 56 ZACTIMA 56 PROCHYMAL 56 Trofex 56 CYT# potent vascular disrupting 56 riociguat 56 elesclomol 56 Exelixis EXEL 56 decitabine 56 tubulin inhibitor 56 sodium glucose cotransporter 56 Icatibant 56 parathyroid hormone PTH 56 Oral NKTR 56 proteasome inhibitor 56 OHR/AVR# 56 Ardea Biosciences 56 Tanespimycin 56 ascending dose 56 Aurexis 56 novel topoisomerase 56 NCCTG 56 FTY# 56 Panzem R 56 JAK2 inhibitor 56 adecatumumab MT# 56 Corlux 56 investigational drug 56 MTP inhibitor 56 AVN# [001] 56 ZOLINZA 56 Cannabinor 56 Annamycin 56 posaconazole 56 tipifarnib 56 alvimopan 56 ularitide 56 sunitinib 56 PI3K inhibitor 56 Cotara 56 Blinatumomab 56 PHX# 56 p# inhibitor 56 pramlintide 56 ARQL 56 Phase 2a Clinical Trial 56 MLN# 56 tolerability 56 entinostat 56 NGX# 56 HCV NS5B polymerase 56 cyclophilin inhibitor 56 non nucleoside 56 Ziopharm 56 aflibercept 56 PARP inhibitor 56 depsipeptide 56 Opexa 56 highly selective inhibitor 56 Azixa 56 deforolimus 56 investigational compounds 56 viral kinetics 56 Phase #b/#a clinical 56 metreleptin 56 vascular disrupting agent 56 CB2 selective receptor agonist 56 INT# [002] 56 Vilazodone 56 sapacitabine 56 initiate Phase 1b 56 Chemophase 56 Enzastaurin 55 Phase 2b clinical trials 55 CEQ# 55 μg dose 55 XL# XL# 55 Exherin TM 55 receptor agonist 55 lesinurad 55 partial agonist 55 methylnaltrexone 55 Vidofludimus 55 Nexavar ® 55 DU #b 55 afatinib 55 BCX# 55 registrational 55 HCD# [002] 55 DPP4 inhibitor 55 HZT 55 Ceflatonin R 55 DAPT 55 bortezomib Velcade R 55 ruxolitinib 55 integrase inhibitor 55 PRX# 55 JAK2 inhibitors 55 sorafenib tablets 55 AAG geldanamycin analog 55 Tranzyme 55 EOquin TM 55 pivotal Phase III 55 voreloxin 55 Vandetanib 55 tesmilifene 55 Asentar 55 Imprime PGG 55 histone deacetylase inhibitor 55 refractory CLL 55 PDX pralatrexate 55 Cinquil 55 telomerase therapeutic 55 RH1 55 mixed dyslipidemia 55 PROMACTA 55 Æterna Zentaris 55 Fibrillex TM 55 Anticalin R 55 Pyridorin TM 55 relapsing remitting multiple sclerosis 55 CIMZIA ™ 55 Dr. Fahar Merchant 55 Pertuzumab 55 romidepsin 55 inhibitor RG# 55 Telaprevir VX 55 Phase IIIb clinical 55 BAL# [002] 55 vandetanib 55 PREZISTA r 55 dose escalation Phase 55 preclinical compounds 55 lintuzumab SGN 55 BMN 55 investigational monoclonal antibody 55 Tarceva TM 55 active comparator 55 mg BID 55 DermaVir Patch 55 Menerba 55 randomized Phase III 55 clinical pharmacology studies 55 ISTODAX 55 LAF# 55 NOX E# 55 AVE# 55 IMGN 55 systemically administered 55 dose limiting toxicities 55 humanized anti 55 reslizumab 55 Atrasentan 55 velafermin belinostat 55 Darusentan 55 Acadia Pharmaceuticals 55 farletuzumab 55 bortezomib Velcade 55 GSK# [002] 55 MAb 55 Viramidine 55 tyrosine kinase inhibitor 55 Maribavir 55 plus prednisone 55 Phase #/#a 55 Varespladib 55 multiple ascending dose 55 systemic RNAi therapeutic 55 baminercept 55 immunomodulating 55 small molecule inhibitor 55 TASKi2 55 lacosamide 55 BRIM2 55 QLT# 55 Voreloxin 55 pan histone deacetylase 55 xenograft models 55 bosutinib 55 PLX# 55 reversible inhibitor 55 BZL# 55 AZILECT R 55 Irinotecan 55 CD3 monoclonal antibody 55 Dacogen injection 55 intranasal formulation 55 TELCYTA 55 aflibercept VEGF Trap 55 VA# [002] 55 Lixivaptan 55 HDACi 55 vicriviroc 55 Phase IIb Trial 55 oral picoplatin 55 echinocandin 55 Ophena TM 55 tolerability profiles 55 IAP inhibitor 55 Tarvacin TM 55 TACI Ig 55 iloprost 55 trodusquemine 55 Initiate Phase 55 MDV# 55 oritavancin 55 Ambrisentan 55 galiximab 55 Catena ® 55 antibody MAb 55 pharmacokinetic PK profile 55 analgesic efficacy 55 EOquin 55 alfa 2a 55 peripherally acting 55 teplizumab 55 crizotinib PF # 55 VentiRx 55 drug conjugate 55 IMC #B 55 Allovectin 7 ® 55 dose escalation 55 ritonavir boosted 55 Aegera 55 ARQ 55 interferon gamma 1b 55 thymalfasin 55 XL# SAR# 55 sulodexide 55 LymphoStat B TM 55 Hana Biosciences 55 ARRY # 55 Velcade bortezomib 55 heavily pretreated patients 55 Talactoferrin 55 Calistoga Pharmaceuticals 55 IMGN# 55 metastatic castration resistant 55 HER2 positive metastatic breast 55 E2F Decoy 55 oral bioavailability 55 CDP# 55 nab paclitaxel 55 Rexahn Pharmaceuticals 55 novel peptide 55 FOLFOX6 chemotherapy regimen 55 Hsp# inhibition 55 Protelos 55 highly selective adenosine 55 glucokinase activator 55 APD# 55 vorinostat 55 intravenously administered 55 novel histone deacetylase 55 ATL/TV# 55 GSK # 55 preclinical models 55 cancer immunotherapies 55 Neulasta ® 55 ceftazidime 55 ruboxistaurin 55 viral kinetic 55 Viprinex TM 55 hematologic malignancies 55 GRN# 55 Revlimid lenalidomide 55 rHuPH# 55 Tasimelteon 55 Pradefovir 54 CGEN # 54 Phase III placebo controlled 54 opioid induced bowel dysfunction 54 EQUIP OB 54 VEGF receptor 54 Myocet 54 Apoptone 54 Combination REOLYSIN R 54 6R BH4 54 antisense drug 54 direct thrombin inhibitors 54 targeted radiotherapeutic 54 Halozyme Therapeutics 54 ALB # 54 Targretin 54 Tolvaptan 54 IAP inhibitors 54 mg TID 54 alpha 2a 54 anticancer agents 54 ILUVIEN ® 54 docetaxel chemotherapy 54 TTF Therapy 54 selective kinase inhibitor 54 BRIM3 54 Pharmacokinetics PK 54 alpha antagonist 54 APOPTONE 54 ulimorelin 54 placebo controlled clinical 54 CTCE 54 tgAAC# 54 omacetaxine 54 plasma kallikrein inhibitor 54 Telintra 54 pharmacokinetics 54 AEterna 54 zileuton 54 IMiDs 54 epothilones 54 REP# 54 rFIXFc 54 Phase 1b clinical trials 54 Phase 1b dose escalation 54 APTIVUS 54 calcitonin 54 hematological tumors 54 epothilone 54 generation Hsp# inhibitor 54 biologic therapy 54 novel immunomodulatory 54 Zenvia ™ 54 Talabostat 54 DDP# 54 ozarelix 54 hematological cancers 54 daunorubicin 54 laquinimod 54 SU# [003] 54 long acting muscarinic 54 OMP #R# 54 relapsed MM 54 MYCAMINE 54 Microplasmin 54 Immunogen 54 Rebif ® 54 TRIOLEX 54 Pervasis 54 Sunesis Pharmaceuticals 54 P#X# antagonist 54 rFVIIIFc 54 potent inhibitor 54 nucleotide analog 54 beta 1a 54 QuatRx 54 COPAXONE R 54 CIMZIA TM certolizumab pegol 54 pharmacokinetic PK study 54 GAP #B# 54 Dasatinib 54 Cloretazine 54 eltrombopag 54 LibiGel Phase III 54 APTIVUS r 54 TLR8 agonist 54 Clavis Pharma 54 Pharmacokinetic studies 54 elacytarabine 54 Vectibix monotherapy 54 ELND# 54 pegylated interferon alfa 2a 54 Syncria 54 Zoraxel 54 imatinib mesylate 54 investigational hepatitis C 54 Posiphen 54 mg dose 54 generation proteasome inhibitor 54 pitavastatin 54 #I TM# 54 dasatinib Sprycel ® 54 diabetic nephropathy 54 Valdoxan 54 ToGA 54 EndoTAG 54 AZD# 54 PPAR gamma agonist 54 Tesetaxel 54 IL# PE#QQR 54 ACTEMRA TM 54 Trastuzumab 54 5 HT6 receptor 54 FTY# fingolimod 54 tasimelteon 54 adecatumumab 54 erlotinib Tarceva 54 Alemtuzumab 54 Panzem NCD 54 S/GSK# 54 clevidipine 54 JAK3 54 CXA 54 TBC# 54 II Clinical Trial 54 Ventavis 54 anti angiogenic agents 54 prodrug 54 Ostabolin C 54 Viprinex 54 TMC# C# 54 mTOR inhibitors 54 NS#/#A protease 54 Exelixis compounds 54 Idenix Pharmaceuticals 54 pharmacodynamic PD 54 antitumour activity 54 metastatic renal cell carcinoma 54 GENR 54 Sulonex 54 demonstrated antitumor activity 54 Romidepsin 54 Phase #/#a trial 54 samarium Sm 54 aclidinium 54 SEROQUEL 54 ALN VSP 54 PLK1 SNALP 54 thiazolides 54 ARIKACE 54 alefacept 54 tolvaptan 54 isoform selective 54 Insegia 54 RDEA 54 TG MV 54 BENICAR HCT 54 celgosivir 54 Zemiva 54 bafetinib 54 tremelimumab 54 Amigal 54 aleglitazar 54 diarrhea predominant irritable 54 Fx #A 54 renin inhibitor 54 GOUT 54 MEK Inhibitor 54 picoplatin 54 pharmacokinetics PK 54 proteasome inhibitors 54 darunavir ritonavir 54 maximally tolerated dose 54 CCR5 antagonist 54 ceftaroline 54 Lenocta 54 PEGylated irinotecan 54 safety tolerability pharmacokinetic 54 alfimeprase 54 myeloproliferative disorders 54 dasatinib Sprycel 54 SABCS 54 EXPAREL TM 54 Nasdaq OPTR 54 Meets Primary Endpoint 54 multicenter Phase 54 Celsion Corporation 54 generation antisense 54 INCB# [003] 54 vemurafenib 54 SUCCEED trial 54 SUTENT 54 triphendiol 54 LAS# [002] 54 temsirolimus 54 olaparib 54 LUX Lung 54 ACZ# 54 Anticalin 54 refractory NSCLC 54 PEG IFN 54 bronchodilation 54 tasocitinib 54 PKC# 54 Onconase 54 oral Xeloda 54 Ozarelix 54 refractory gout 54 Pivotal Phase III 54 lixisenatide 54 docetaxel Taxotere ® 54 R sorafenib tablets 54 FOLOTYN 54 HCV nucleotide polymerase inhibitor 54 blinatumomab 54 transthyretin TTR mediated amyloidosis 54 Keryx Biopharma 54 Hsp# Inhibitor 54 relapsed refractory 54 ENZN 54 SYN# 54 Empatic 54 Seattle Genetics SGEN 54 PEGPH# 54 Androxal TM 54 Nanobody ® 54 Vicriviroc 54 controlled multicenter Phase 54 Omnitarg 54 metastatic RCC 54 tezampanel NGX# 54 Telaprevir 54 octreotide 54 Alagebrium 54 elvucitabine 54 PTK ZK 54 denufosol 53 YONDELIS R 53 Ixempra 53 Cellgate 53 R roscovitine 53 retapamulin 53 nitric oxide donating 53 hypoxia activated prodrug 53 Addrenex 53 Allovectin 7 R 53 ONCONASE 53 Teriflunomide 53 BrachySil TM 53 pharmacodynamic properties 53 CCX# B 53 mGluR5 negative 53 DCCR 53 heavily pretreated 53 budesonide foam 53 midstage trials 53 CCR9 53 Avanafil 53 subcutaneously administered 53 Zerenex 53 Aliskiren 53 potent antiviral 53 tumor xenograft models 53 Silodosin 53 subcutaneous formulation 53 ZEVALIN ® 53 NASDAQ ARRY 53 MBP# [001] 53 Treanda 53 novel prodrug 53 IMiDs R 53 Amplimexon 53 Leukine 53 non nucleoside HCV 53 Clolar ® 53 anti fibrotic 53 protease inhibitor 53 pharmacodynamic effects 53 novel VDA molecule 53 SPIRIT IV 53 Diabetic Macular Edema DME 53 Mpex 53 Zolinza 53 NASDAQ SGEN 53 eosinophilic asthma 53 endothelin receptor antagonists 53 multitargeted 53 trabedersen 53 Celator 53 cathepsin K inhibitor 53 hematological malignancies 53 iSONEP 53 Tolerx 53 Cetrorelix 53 Fc fusion protein 53 vascular disrupting agents 53 Lupuzor 53 hA# 53 immunomodulatory 53 Belinostat 53 standard chemotherapy regimen 53 Marqibo 53 alemtuzumab Campath 53 IIa trial 53 TOLAMBA 53 ICA # 53 double blinded randomized 53 cediranib 53 Vertex Pharma 53 phase Ib clinical 53 MOGN